#Canada #Toronto #Cardiol Therapeutics #CardiolRx #MAVERIC Program

Cardiol Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Toronto, Canada - On September 14, 2026, at 10:30 a.m. EDT, Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) will be featured in a Fireside Chat during the H.C. Wainwright 28th Annual Global Investment Conference held at the Lotte New York Palace Hotel in New York City. This participation is significant for the company as it seeks to advance its innovative therapies aimed at combating heart disease, particularly anti-inflammatory and anti-fibrotic treatments.

The session can be accessed via a live webcast available on Cardiol's investor relations website, where interested parties can catch up on the latest advancements in cardiac therapies and the company’s strategic insights.

About Cardiol Therapeutics

Cardiol Therapeutics is a pioneering organization focused on late-stage life sciences. Their primary objective is to develop cutting-edge anti-inflammatory and anti-fibrotic therapies targeting various heart conditions. The flagship drug candidate, CardiolRx™, stands at the forefront of their research, modulating key immune responses associated with inflammation and fibrosis prevalent in conditions like pericarditis, myocarditis, and heart failure.

Advancements and Programs

CardiolRx™ is currently being evaluated through two major research programs: the MAVERIC Program, which addresses recurrent pericarditis, and the ARCHER Program that focuses on acute myocarditis. The MAVERIC program, for instance, includes the ongoing pivotal Phase III MAVERIC trial—that seeks to underscore the efficacy of CardiolRx™ for patients suffering from this debilitating condition characterized by severe chest pain and fatigue.
The U.S. FDA has recognized CardiolRx™ by granting it Orphan Drug Designation, a status that emphasizes the drug’s potential in treating rare but serious health issues related to pericarditis. Meanwhile, the ARCHER Program demonstrated substantial progress through the completed Phase II trial focused on assessing CardiolRx’s safety and tolerability among young adults at risk of acute heart failure.

Moreover, the company is also on a path to develop CRD-38, a novel subcutaneous drug formulation aimed at tackling inflammatory heart diseases, bolstering Cardiol's commitment to fighting this leading cause of mortality and hospitalization globally. The growing healthcare expenditure associated with heart diseases, particularly in the U.S., which surpasses $30 billion annually, underscores the essential nature of this research.

Looking Ahead

During the Fireside Chat, executives from Cardiol are expected to delve into the opportunities that lie ahead for the company, emphasizing the promising results from ongoing trials and the potential impact of their therapies in clinical practice. The event is not only an opportunity for funding discussions but also for raising awareness about the critical nature of heart health and the innovative solutions Cardiol is bringing to market.

For those interested in learning more about Cardiol Therapeutics and insights from the upcoming Fireside Chat, more details can be found on their official website: CardiolRx.com.

Conclusion

The 28th Annual Global Investment Conference is a pivotal event for Cardiol Therapeutics as it seeks to position itself at the cutting edge of heart disease innovation. As cardiovascular diseases continue to pose significant challenges worldwide, Cardiol's work in developing effective treatments is not just timely but essential for improving patient outcomes in the face of this ongoing health crisis.